Nov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post-surgical adjuvant treatment f..
The Food and Drug Administration (FDA) approved Encorafenib (Braftovi, Array BioPharma Inc., a wholly owned subsidiary of Pfizer) and binimetinib (Mektovi, Array BioPharma Inc.) in November 2023 as medicines that can be used to t..
August 2023: Pralsetinib (Gavreto, Genentech, Inc.) was given regular approval by the Food and Drug Administration for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), as determined by an FDA..
Feb 2023: For stage IB (T2a 4 cm), stage II, or stage IIIA non-small cell lung cancer, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) as adjuvant therapy after resection and platinum-based chemoth..
November 2022: The combination of tremelimumab (Imjudo, AstraZeneca Pharmaceuticals), durvalumab (Imfinzi, AstraZeneca Pharmaceuticals), and platinum-based chemotherapy was approved by the Food and Drug Administration for adult pa..
Noiembrie 2022: Combinația de cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) și chimioterapie pe bază de platină pentru pacienții adulți cu cancer pulmonar fără celule mici (NSCLC) avansat fără anomalii EGFR, ALK sau ROS1.
August 2022: Pentru pacienții adulți cu cancer pulmonar fără celule mici (NSCLC) metastatic ale căror tumori au o mutație care duce la omiterea exonului 14 de tranziție mezenchimato-epitelială (MET), așa cum a fost detectat de un test aprobat de FDA, Food..
August 2022: Pentru pacienții adulți cu cancer pulmonar fără celule mici (NSCLC) metastatic ale căror tumori au o mutație care duce la omiterea exonului 14 de tranziție mezenchimato-epitelială (MET), așa cum a fost detectat de un test aprobat de FDA, Food..
March 2022: In the neoadjuvant setting, the FDA approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with platinum-doublet chemotherapy for adult patients with resectable non-small cell lung cancer (NSCLC).Thi..
Nov 2021: Food and Drug Administration a aprobat atezolizumab (Tecentriq, Genentech, Inc.) pentru tratamentul adjuvant la pacienții cu cancer pulmonar fără celule mici (NSCLC) în stadiul II până la IIIA ale căror tumori conțin expresia PD-L1 o..